Tumor Genomic Profiling denied for failing step therapy by Avalon Healthcare Solutions?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Avalon Healthcare Solutions typically requires
Avalon manages genetic/molecular testing UM for many BCBS plans. Tumor profiling per NCCN biomarker recommendations.
What works in the appeal
Confirm Avalon network status — reroute to in-network lab if denial is purely contractual. NCCN biomarker testing recommendations require panel-based testing (NSCLC: EGFR/ALK/ROS1/BRAF/KRAS/MET/RET/NTRK/ERBB2/PD-L1). ACOG #226 (2020) — cfDNA offered to all pregnancies.
The Avalon Healthcare Solutions angle on Tumor Genomic Profiling
## Why Avalon Healthcare Solutions Applies Step Therapy to Tumor Genomic Profiling — and How to Appeal
Tumor genomic profiling encompasses broad molecular panel tests and comprehensive genomic sequencing that identify actionable mutations in a cancer specimen. Avalon Healthcare Solutions manages laboratory benefits for multiple health plans and applies tiered coverage policies that can require certain diagnostic prerequisites — essentially a step-therapy analog applied to testing — before authorizing comprehensive sequencing.
### Why This Denial Happens
Avalon's step-therapy-style policies on genomic testing typically require that narrower, less costly tests (such as single-gene or small hotspot panels) be performed and found insufficient before a comprehensive genomic profile is approved. If the clinical record does not clearly document that a more targeted approach was tried or considered and found inadequate for the patient's clinical question, Avalon may deny the comprehensive test on the grounds that a prior diagnostic step was skipped.
### Why It Is Appealable
Step-therapy logic is designed for situations where the earlier step is genuinely equivalent. For many cancer presentations — particularly rare histologies, unusual presentations, cancers of unknown primary, or patients whose disease has progressed on standard therapy — a targeted single-gene approach cannot answer the clinical question that drives treatment selection. When your oncologist can document why a narrower test is clinically insufficient in this specific case, the step-therapy denial becomes directly challengeable.
### Federal Appeal Framework
- Internal appeal: File within the window on your denial notice (commonly 180 days). Plans must respond within 30 days (pre-service) or 60 days (post-service).
- External review (ACA §2719): After exhausting the internal process, request independent external review. The filing window is typically around four months from the final internal denial. An IRO issues a binding decision independent of Avalon or the insurer.
- ERISA §503: Employer-plan members are entitled to a full-and-fair review and may demand the complete administrative record, including the clinical criteria Avalon applied.
- Expedited review: Available when a delay in testing would seriously jeopardize health or the ability to undergo time-sensitive treatment; decisions are generally required within 72 hours.
### Documentation to Gather
1. Diagnosis and histology confirmation — current pathology report establishing the cancer type, stage, and any morphologic features that make targeted testing inadequate. 2. Clinical rationale for skipping narrower testing — chart documentation or a letter explaining why a limited hotspot or single-gene panel would not provide sufficient information for treatment planning in this case. 3. Treatment history — records of prior systemic therapies, responses, and progression events that make comprehensive profiling clinically necessary now. 4. Ordering oncologist's medical-necessity letter — a signed narrative explaining what actionable information the comprehensive panel is expected to yield and how it will directly affect the treatment plan. 5. Relevant guideline support — reference to the applicable NCCN guideline or equivalent society recommendation supporting comprehensive genomic testing in this clinical scenario.
### Criteria-Mapping Structure
Obtain Avalon's published policy for the specific test code requested. List every stated coverage criterion. For each criterion, provide the corresponding chart fact, date, and source document. Where the policy requires a prior diagnostic step, document explicitly why that step was either completed, clinically inappropriate, or insufficient. Submit this mapping as a structured cover memo so the reviewer must engage with each criterion individually rather than applying a blanket step-therapy rejection.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →